期刊文献+

盐酸倍他司汀片联合盐酸氟桂利嗪片对椎-基底动脉供血不足性眩晕症患者椎基底动脉血流动力学和生活质量的影响 被引量:35

Effects of Betahistine Hydrochlonde Tablet Combined With Flunarizine Hydrochloride Tablet on Vertebrobasilar Hemodynamics and Quality of Life in Patients with Vertebrobasilar Insufficiency Vertigo
原文传递
导出
摘要 目的:观察盐酸倍他司汀片联合盐酸氟桂利嗪片对椎-基底动脉供血不足(VBI)性眩晕症患者椎基底动脉血流动力学和生活质量的影响。方法:选择2019年5月~2021年2月期间来我院就诊的97例VBI性眩晕症患者,根据乱数表法,入选的患者分为对照组和观察组,分别为48例和49例,对照组接受盐酸倍他司汀片治疗,观察组接受盐酸倍他司汀片联合盐酸氟桂利嗪片治疗,均治疗2周。对比两组疗效、药物不良反应、眩晕症状评分、生活质量、椎基底动脉血流动力学情况。结果:观察组的临床总有效率(93.88%)高于对照组(72.92%)(P<0.05)。治疗2周后,观察组的眩晕评定量表的评分系统(DARS)、眩晕障碍量表(DHI)评分低于对照组(P<0.05)。治疗2周后,观察组的36项健康调查简表(SF-36)各维度评分均高于对照组(P<0.05)。治疗2周后,观察组的左侧/右侧椎动脉及基底动脉血流速度较对照组高(P<0.05)。两组不良反应发生率对比无差异(P>0.05)。结论:盐酸倍他司汀片联合盐酸氟桂利嗪片治疗VBI性眩晕症患者疗效显著,可有效改善其椎基底动脉血流动力学状况,缓解眩晕症状,提高生活质量。 Objective: To observe the effects of betahistine hydrochlonde tablet combined with flunarizine hydrochloride tablet on vertebrobasilar hemodynamics and quality of life in patients with vertebrobasilar insufficiency(VBI) vertigo. Methods: 97 patients with VBI vertigo who came to our hospital from May 2019 to February 2021 were selected. According to the random number table method,the selected patients were divided into control group and observation group, 48 cases and 49 cases respectively. The control group was treated with betahistine hydrochlonde tablet, and the observation group was treated with betahistine hydrochlonde tablet combined with flunarizine hydrochloride tablet, all patients were treated for 2 weeks. The curative effect, adverse drug reactions, vertigo symptom score,quality of life and vertebrobasilar hemodynamics were compared between the two groups. Results: The total clinical effective rate of the observation group(93.88%) was higher than that of the control group(72.92%)(P<0.05). 2 weeks after treatment, the scores of vertigo Assessment Scale(DARS) and vertigo Disorder Questionnaire(DHI) of the observation group were lower than those of the control group(P<0.05). 2 weeks after treatment, the scores of each dimensions of 36-Item Health Survey(SF-36) of the observation group were higher than those of the control group(P<0.05). 2 weeks after treatment, the blood flow velocities of left/right vertebral artery and basilar artery of the observation group were higher than those of the control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion: Betahistine hydrochlonde tablet combined with flunarizine hydrochloride tablet in the treatment of patients with VBI vertigo has a significant effect, can effectively improve the vertebrobasilar artery blood flow dynamics, relieve vertigo symptoms, improve the quality of life.
作者 孙丽燕 李景莉 李亚楠 李宏锦 王淑珍 SUN Li-yan;LI Jing-li;LI Ya-nan;LI Hong-jin;WANG Shu-zhei(Department of Internal Medicine-Neurology,The First Affiliated Hospital of Hebei North University,Zhangjiakou,Hebei,075000,China;Department of Internal Medicine-Neurology,The 81st Group Military Hospital of People's Liberation Army Ground Force,Zhangjiakou,Hebei,075000,China)
出处 《现代生物医学进展》 CAS 2022年第3期491-494,499,共5页 Progress in Modern Biomedicine
基金 河北省张家口市重点研发计划项目(1921115D) 河北省自然科学基金项目(H2015105062)。
关键词 盐酸倍他司汀片 盐酸氟桂利嗪片 椎-基底动脉供血不足性眩晕症 血流动力学 生活质量 Betahistine hydrochlonde tablet Flunarizine hydrochloride tablet Vertebrobasilar insufficiency vertigo Hemodynamic monitoring Quality of life
  • 相关文献

参考文献13

二级参考文献112

共引文献1297

同被引文献336

引证文献35

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部